ASX - Delayed Quote AUD

Clarity Pharmaceuticals Ltd (CU6.AX)

4.6200

-0.5500

(-10.64%)

As of 1:10:07 PM GMT+11. Market Open.

Clarity Pharmaceuticals Ltd's (ASX:CU6) top owners are individual investors with 58% stake, while 18% is held by insiders

Key Insights The considerable ownership by individual investors in Clarity Pharmaceuticals indicates that they...

Simply Wall St. last month

CLRPF
Copper-67 SAR-bisPSMA updates

Copper-67 SAR-bisPSMA updates

PR Newswire last month

CLRPF
Positive guidance from the U.S. FDA on 64Cu-SAR-bisPSMA Phase III trial in patients with recurrence of prostate cancer

Clarity Pharmaceuticals (ASX: CU6) ("Clarity", "the Company"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce it will be commencing a pivotal Phase III trial of its 64Cu-SAR-bisPSMA diagnostic in patients with BCR of prostate cancer following a successful end of phase meeting with the U.S. FDA. The trial, named AMPLIFY (64Cu-SAR-bisPSMA Positron Emission To

PR Newswire last month

CLRPF
Market Sentiment Around Loss-Making Clarity Pharmaceuticals Ltd (ASX:CU6)

Clarity Pharmaceuticals Ltd ( ASX:CU6 ) is possibly approaching a major achievement in its business, so we would like...

Simply Wall St. 2 months ago

CLRPF
SECuRE trial advances: No dose limiting toxicities and strong preliminary efficacy data in first multi-dose cohort

Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce an update on the safety review of the first 3 participants enrolled in cohort 4 of the SECuRE trial who received 2 doses of 67Cu-SAR-bisPSMA. Cohort 4 is the final cohort in the dose escalation phase of the study, with participants receiving a minimum of 2 and a m

PR Newswire 2 months ago

CLRPF
Here's Why We're Not Too Worried About Clarity Pharmaceuticals' (ASX:CU6) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Clarity...

Simply Wall St. 3 months ago

CLRPF
Clarity receives FDA Fast Track Designation for 64Cu-SAR-bisPSMA

Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for 64Cu-SAR-bisPSMA for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive prostate cancer lesions with suspected metastasis who are

PR Newswire 3 months ago

CLRPF
Codan Leads Three Undervalued Small Caps With Insider Actions In Australia

In recent trading sessions, the Australian market has shown mixed signals with the ASX200 marginally up by 0.1%. Notably, the IT sector outperformed, gaining 0.9%, while materials faced a downturn, nearly losing 1%. In such a fluctuating environment, identifying undervalued small-cap stocks like Codan that show potential for growth becomes crucial for investors looking for opportunities amidst broader market movements.

Simply Wall St. 5 months ago

NURPF

CODAF

CLRPF
Exploring Undervalued Small Caps With Insider Actions In June 2024

As global markets exhibit a mix of cautious optimism and selective growth, with the S&P 500 reaching new highs and modest gains across major indices, investors are keenly observing market dynamics. In this environment, undervalued small-cap stocks, particularly those with insider buying actions, could present intriguing opportunities for discerning investors looking to potentially capitalize on overlooked value in the current economic landscape.

Simply Wall St. 5 months ago

HMDPF

CLRPF

1277.HK
Exploring Undervalued Small Caps With Insider Actions In Australia June 2024

In recent times, the Australian market has shown a steady increase, rising 8.9% over the past year despite remaining flat in the last week. Given these conditions and with earnings expected to grow by 14% annually in the near future, undervalued small caps with insider buying actions can present intriguing opportunities for investors looking to potentially benefit from market inefficiencies.

Simply Wall St. 5 months ago

CLRPF

NURPF

CODAF
Is Clarity Pharmaceuticals Ltd (ASX:CU6) Trading At A 48% Discount?

Key Insights Clarity Pharmaceuticals' estimated fair value is AU$9.82 based on 2 Stage Free Cash Flow to Equity Clarity...

Simply Wall St. 6 months ago

CLRPF
Clarity's theranostic prostate cancer trial advances to multi-dose phase

Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the successful completion of cohort 3 and advancement to cohort 4, the first multi-dose cohort in the SECuRE trial.

PR Newswire 8 months ago

CLRPF
Additional COBRA results: SAR-bisPSMA detects lesions in the 2-millimetre range

Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to share additional data from its diagnostic 64Cu-SAR-bisPSMA trial, COBRA (NCT05249127)[1].

PR Newswire 8 months ago

CLRPF
First patient dosed in Clarity's registrational Phase III prostate cancer trial with Cu-64 SAR-bisPSMA

Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that the first patient has been dosed in its pivotal Phase III 64Cu-SAR-bisPSMA diagnostic trial in prostate cancer, CLARIFY (NCT06056830)1, at the Urology Cancer Center / XCancer Omaha, NE.

PR Newswire 11 months ago

CLRPF

Performance Overview

Return	CU6.AX	S&P/ASX 200 [XJO]
YTD	+143.16%	+9.74%
1-Year	+173.37%	+15.14%
3-Year	+516.00%	+13.28%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Clarity Pharmaceuticals Ltd (CU6.AX)

Clarity Pharmaceuticals Ltd's (ASX:CU6) top owners are individual investors with 58% stake, while 18% is held by insiders

Copper-67 SAR-bisPSMA updates

Positive guidance from the U.S. FDA on 64Cu-SAR-bisPSMA Phase III trial in patients with recurrence of prostate cancer

Market Sentiment Around Loss-Making Clarity Pharmaceuticals Ltd (ASX:CU6)

SECuRE trial advances: No dose limiting toxicities and strong preliminary efficacy data in first multi-dose cohort

Here's Why We're Not Too Worried About Clarity Pharmaceuticals' (ASX:CU6) Cash Burn Situation

Clarity receives FDA Fast Track Designation for 64Cu-SAR-bisPSMA

Codan Leads Three Undervalued Small Caps With Insider Actions In Australia

Exploring Undervalued Small Caps With Insider Actions In June 2024

Exploring Undervalued Small Caps With Insider Actions In Australia June 2024

Is Clarity Pharmaceuticals Ltd (ASX:CU6) Trading At A 48% Discount?

Clarity's theranostic prostate cancer trial advances to multi-dose phase

Additional COBRA results: SAR-bisPSMA detects lesions in the 2-millimetre range

First patient dosed in Clarity's registrational Phase III prostate cancer trial with Cu-64 SAR-bisPSMA

Performance Overview